TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01746173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Study: NCT00751192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV-testing motivational videos
Study: NCT01746173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00751192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard public health text
Study: NCT01746173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Study: NCT03401268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous immunoglobulin
Description: 24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
Study: NCT01354119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic stent-graft
Description: Early intervention with aortic stent-graft
Study: NCT03771274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis ZLB00 & Symfony IOL
Description: The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
Study: NCT01344070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of the 15 drugs listed below
Description: single, oral, immediate-release, non-combinational innovator formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of the 15 drugs listed below
Description: single, oral, immediate-release, non-combinational generic formulation a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of the 15 drugs listed below
Description: single, oral, immediate-release, non-combinational generic formulation b
Study: NCT03086486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200mg tablets
Study: NCT01344070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of the 15 drugs listed below
Description: single, oral, immediate-release, non-combinational generic formulation c
Study: NCT04033783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6MWT - accompanied
Description: Assessor walks behind the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6MWT - not accompanied
Description: Assessor does not walk behind the patient
Study: NCT00567411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine 0.1%
Description: 1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apraclonidine 0.5%
Description: 1 drop applied 1 hour prior to SLT
Study: NCT01835002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrostimulation
Description: Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
Study: NCT02240602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 1.00 mg dose
Description: Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.03 mg/kg dose
Description: Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.02 mg/kg dose
Description: intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
Study: NCT00873184

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Massage Therapy
Description: The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
Study: NCT04165629

Intervention type: DRUG
Intervention: Aspirin 300mg and Clopidogrel 300mg
Description: Aspirin 300mg and Clopidogrel 300mg on the day of the PTA

Intervention type: DRUG
Intervention: Aspirin 300mg and Clopidogrel 300mg
Description: Aspirin 300mg and Clopidogrel 300mg on the day of the PTA

Intervention type: DRUG
Intervention: Aspirin 300mg and Clopidogrel 300mg
Description: Aspirin 300mg and Clopidogrel 300mg on the day of the PTA

Intervention type: DRUG
Intervention: Aspirin 300mg and Clopidogrel 300mg
Description: Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
Study: NCT04517643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therasphere Therapy
Description: TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
Study: NCT01007838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training programme
Description: Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: Lower body stretching exercise using the easiest rehabilitation elastic Theraband
Study: NCT03086486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200mg tablets
Study: NCT01007838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: Lower body stretching exercise using the easiest rehabilitation elastic Theraband
Study: NCT04348006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 3.5 MG
Description: VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)
Study: NCT02574689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIPP
Description: The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness contact control
Description: Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials.
Study: NCT03147534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InstaTemp MD
Description: The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InstaTemp MD
Description: The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InstaTemp MD
Description: The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allyn, rectal
Description: The Welch Allyn rectal thermometer is intended to measure human body temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allyn, rectal
Description: The Welch Allyn rectal thermometer is intended to measure human body temperature.
Study: NCT03161028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: 1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
Study: NCT03147534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allyn, oral
Description: The Welch Allyn oral thermometer is intended to measure human body temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien, tympanic
Description: The Covidien tympanic thermometer is intended to measure human body temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien, tympanic
Description: The Covidien tympanic thermometer is intended to measure human body temperature.
Study: NCT03581838

Intervention type: BEHAVIORAL
Intervention: Observed eating session
Description: Eating a Jimmy Johns turkey or vegetarian sandwich

Intervention type: BEHAVIORAL
Intervention: Observed eating session
Description: Eating a Jimmy Johns turkey or vegetarian sandwich

Intervention type: BEHAVIORAL
Intervention: Observed eating session
Description: Eating a Jimmy Johns turkey or vegetarian sandwich
Study: NCT01616251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake
Description: 4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake
Description: 4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake
Description: 4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake
Description: 4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
Study: NCT03052816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ice T
Description: Ice/Tylenol/Toradol with dilaudid for breakthrough

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin/Percocet/Dilaudid for breakthrough
Description: Standard regimen
Study: NCT01359228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (XIFAXAN)
Description: Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet three times a day for 14 days.
Study: NCT01533142

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
Study: NCT00999297

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dihydrocapsiate
Description: Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocapsiate
Description: Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocapsiate
Description: Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Study: NCT00562991

Intervention type: DEVICE
Intervention: measurement of exhaled NO is used to guide treatment
Description: exhaled NO
Study: NCT03588936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (.25 mg/kg)
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 2 doses of tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 2 doses of tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (.5 mg/kg)
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Study: NCT00649402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
Description: 10/120mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® Capsules 10 mg/20 mg
Description: 10/20mg, single dose fed
Study: NCT03413709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Formation Program
Description: The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
Study: NCT00996983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziconotide
Description: intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
Study: NCT01392209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bevacizumab & Stereotactic Radiotherapy
Description: Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
Study: NCT04014569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPSA Algorithm
Description: Insulin dosing will be adjusted using the MPSA Algorithm
Study: NCT03940118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter secretion suctioning
Description: Catheter secretion suctioning with prior nebulization of hypertonic saline

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Secretion suctioning + hypertonic saline
Description: Catheter secretion suctioning with prior nebulization of hypertonic saline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ins-exsufflation
Description: Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ins-exsufflation + Hypertonic saline
Description: Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
Study: NCT01183455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aralast NP
Description: Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusions of placebo once a week for 12 weeks.
Study: NCT05399290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hyclate
Description: 100 mg vs 20 mg doxycycline hyclate BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: 100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
Study: NCT04072263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa 2A
Description: Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy i.v.
Study: NCT00767767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV Saline infusion for 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.45mcg/mL
Description: IV Propofol infusion for 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.90mcg/mL
Description: IV Propofol infusion for 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental 1.5mcg/mL
Description: IV Thiopental 1.5mcg/mL infusion for 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental 3mcg/mL
Description: IV Thiopental 3mcg/mL infusion for 2 hours
Study: NCT00478686

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: 5 to 7.5 milliliter (mL) Blood Sample

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: 5 to 7.5 milliliter (mL) Blood Sample

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: 5 to 7.5 milliliter (mL) Blood Sample
Study: NCT01366729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraTogs
Description: Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cane walking
Description: All walking activities must take place with cane from waking until sleeping
Study: NCT04107207

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger Kombucha
Description: Craft Ginger Kombucha, a fermented black tea

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ginger Water
Description: Placebo
Study: NCT00223249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study: NCT03100175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: strength training for upper and lower limbs fitness and balance work out